| Data | Hora | Fonte | Título | Código | Companhia |
| 17/01/2019 | 07:00 | PR Newswire (US) | Asceneuron Appoints Peter Van Vlasselaer as Chairman | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 02/07/2018 | 17:49 | Edgar (US Regulatory) | Termination of Registration of a Class of Security Under Section 12(b) (15-12b) | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 22/06/2018 | 20:35 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 22/06/2018 | 10:13 | Edgar (US Regulatory) | (25-NSE) | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 22/06/2018 | 10:03 | Edgar (US Regulatory) | Post-effective Amendment to an S-8 Filing (s-8 Pos) | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 22/06/2018 | 09:59 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 22/06/2018 | 09:54 | Edgar (US Regulatory) | Amended Statement of Ownership: Solicitation (sc 14d9/a) | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 22/06/2018 | 09:48 | Edgar (US Regulatory) | Amended Tender Offer Statement by Third Party (sc To-t/a) | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 22/06/2018 | 09:31 | PR Newswire (US) | Lilly Completes Acquisition of ARMO BioSciences | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 23/05/2018 | 10:18 | Edgar (US Regulatory) | Statement of Ownership: Solicitation (sc 14d9) | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 23/05/2018 | 09:49 | Edgar (US Regulatory) | Tender Offer Statement by Third Party (sc To-t) | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 15/05/2018 | 17:52 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 14/05/2018 | 12:38 | PR Newswire (US) | WeissLaw LLP: ARMO BioSciences Inc. Acquisition May Not Be In The Best Interests of ARMO shareholders | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 10/05/2018 | 18:03 | Dow Jones News | Health Care Up Amid Deal Activity -- Health Care Roundup | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 10/05/2018 | 17:43 | Edgar (US Regulatory) | Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c) | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 10/05/2018 | 12:57 | PR Newswire (US) | ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ARMO BioSciences, Inc. | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 10/05/2018 | 10:16 | Dow Jones News | Eli Lilly Buys Immunotherapy Cancer Treatment Company for $1.6 Billion | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 10/05/2018 | 09:41 | PR Newswire (US) | ARMO BioSciences Alert: Johnson Fistel Investigates Proposed Sale of ARMO BioSciences, Inc.; Is $50 a Fair Price? | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 10/05/2018 | 09:05 | Edgar (US Regulatory) | Written Communication Relating to an Issuer or Third Party (sc To-c) | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 10/05/2018 | 08:30 | PR Newswire (US) | Lilly Announces Agreement To Acquire ARMO BioSciences | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 25/04/2018 | 17:18 | GlobeNewswire Inc. | ARMO BioSciences Announces Poster Presentations of Pegilodecakin (AM0010) at the 2018 American Society of Clinical Oncology (... | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 03/04/2018 | 09:00 | GlobeNewswire Inc. | ARMO BioSciences to Participate in Panel on Cytokines at 8th Annual Cancer Immunotherapy Conference | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 02/04/2018 | 09:00 | GlobeNewswire Inc. | ARMO BioSciences Reports FY 2017 Financial Results | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 30/03/2018 | 17:48 | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 29/03/2018 | 09:00 | GlobeNewswire Inc. | ARMO BioSciences Enrolls First Patient in the CYPRESS 2 Trial Evaluating AM0010 in Non-Small Cell Lung Cancer | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 26/03/2018 | 09:00 | GlobeNewswire Inc. | ARMO BioSciences Announces Positive Outcome of First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 16/03/2018 | 18:16 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 12/02/2018 | 13:24 | GlobeNewswire Inc. | ARMO BioSciences, Inc. (Nasdaq: ARMO) to Ring The Nasdaq Stock Market Closing Bell | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |
| 26/01/2018 | 00:09 | PR Newswire (US) | ARMO BioSciences Announces Pricing of Initial Public Offering | NASDAQ:ARMO | Armo Biosciences, Inc. (delisted) |